Sputnik V is more efficient against the Delta variant, says study
India | June 15, 2021 17:23 ISTThe Sputnik V vaccine was accorded emergency use authorization by the Drugs Controller General of India
The Sputnik V vaccine was accorded emergency use authorization by the Drugs Controller General of India
The supply price of Bharat Biotech''s COVID-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday.
Congress leader Rahul Gandhi on Tuesday urged everyone to follow safety rules and get vaccinated saying no one is safe till the time everyone is.
The recruitment for the clinical trial Bharat Biotech's vaccine Covaxin, among children in the age group of 6-12 years will begin at the AIIMS today.
Delhi's All India Institute of Medical Sciences (AIIMS) is expected to begin on Tuesday the recruitment and clinical trials of India's first indigenously developed Covid-19 vaccine, Bharat Biotech's Covaxin, on children.
Bharat Biotech on Saturday said scientific standards and commitment of the indigenously-developed COVID-19 vaccine Covaxin are transparent.
In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixinghopes of Emergency Use Authorisation.
Bharat Biotech's application for approval of indigenous COVID-19 vaccine, Covaxin, has been rejected by the US FDA that cited a lack of sufficient data.
Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics licence application (BLA) for Covaxin.
Covaxin phase 3 full trial results will be made public in July, Bharat Biotech informed on Wendesday. Covaxin is one of the three vaccines other than Oxford's Covishield and Russia's Sputnik V, that are being administered in India.
The Delta variant (B.1.617.2) was first found in India and is the dominant strain in the country, the Beta variant (B.1.351) was first discovered in South Africa.
The Uttar Pradesh government will organise special vaccination booths for street vendors, auto-rickshaw drivers, e-rickshaw and rickshaw drivers in a bid to encourage them to take the jabs.
The Central government on Tuesday also said that it has decided to increase the supply of two made-in-India vaccines - Covishield and Covaxin.
Prime Minister Narendra Modi Monday announced a centralised Covid-19 vaccine policy.
'Each One Pay One' scheme will aim to fund Covid-19 vaccines for the poor.
The Delhi government Monday informed the Delhi High Court that it has directed all government centres, private hospitals and nursing homes here that Covaxin will only be administered to those in the age group of 18-44 years who received it as first dose of anti-COVID vaccine.
AIIMS in Delhi will begin screening of children aged 2 to 18 years for Covaxin trials from today.
The study said that both vaccines-- Covishield and Covaxin-- elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.
Special 'pink booths' will start functioning in Uttar Pradesh from today to encourage women to take Covid vaccine.
The Delhi government on Sunday directed private hospitals and nursing homes to administer Covaxin only to those eligible for the second dose in respect of the 18-44 age group in the month of June or until further orders.
Top News
Latest News
